WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the company approved the grant of equity awards to three new employees with a ...

Fintel reports that on December 17, 2024, Goldman Sachs downgraded their outlook for Apellis Pharmaceuticals (NasdaqGS:APLS) from Buy to Neutral. Analyst Price Forecast Suggests 37.12% Upside As ...

WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan ...

Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) decreased during the last reporting period, falling from 21.48M to 18.04M. This put 19.86% of the company's publicly available shares short.

In a report released yesterday, Lisa Walter from RBC Capital maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $26.00. The company’s shares ...

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $30.00. The company’s ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Analysts at William Blair upped their FY2024 earnings estimates for Apellis Pharmaceuticals in a report issued on Tuesday ...

Investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 ...

$APLS insiders have traded $APLS stock on the open market 46 times in the past 6 months. Of those trades, 0 have been purchases and 46 have been sales.

$APLS insiders have traded $APLS stock on the open market 27 times in the past 6 months. Of those trades, 0 have been purchases and 27 have been sales.